Goodness Growth Holdings, Inc.
GDNS.CN
Canadian Securities Exchange0.63
CAD
- -
- -
Goodness Growth Holdings, Inc.
GDNS.CN
(Canadian Securities Exchange)
Recent
price
0.63
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vireo Growth Inc., formerly Goodness Growth Holdings, Inc. (CSE: GDNS), operates as a vertically integrated multi-state cannabis company focused on providing safe access to quality medical cannabis products and value to patients through cultivation, manufacturing, wholesale, and retail operations; its core offerings include branded products under the Vireo Spectrum line of pre-filled distillate vaporizer pens and cartridges, syringes, bulk oil, softgels, tablets, oral solutions, oral sprays, topical bars, and balms, as well as Vireo Selects distillate vaporizer pens and syringes, alongside cannabis flower, oils, topicals, orally ingestible tablets, capsules, and vaporizer cartridges designed for specific medical conditions like chemotherapy nausea or epilepsy. The company serves medical and consumer markets primarily in Maryland, Minnesota, and New Mexico, with 16 retail dispensaries nationwide emphasizing customer-centric experiences informed by medicine and science; it maintains cultivation and processing facilities such as those in Hurlock, Maryland, and dispensaries in locations including Baltimore, Frederick, and White Plains, New York. Founded in 2014 as Minnesota Medical Solutions, LLC and headquartered in Minneapolis, Minnesota, with a registered office in Vancouver, British Columbia, Vireo Growth recently changed its name from Goodness Growth Holdings in July 2024 to better align with its Vireo Health brand heritage, closed a non-brokered private placement in June 2024 providing capital and secured a credit agreement extension to July 31, 2024, executed a binding term sheet in April 2024 for the divestiture of its New York subsidiary Vireo Health of New York to ACE Venture Enterprises, Inc. for $3.0 million to $5.0 million plus a $20.0 million investment commitment, and reported first-quarter 2024 revenue growth of 44.5% year-over-year excluding discontinued operations and New York.